Dalrada (DFCO). Our 11th and Latest Ten Bagger.
We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
News and Charts on Four Small Cap Telehealth and Remote Health Monitoring Plays.
After Losing $33 Billion in Value, Teladoc Health Snags an Upgrade.
With chances building...
Interview: Ric Schumacher CEO, Pressure Bioscience (PBIO)
Our favorite interview to date, and there have been dozens. Filmed November of 2021, and the story has gotten to much better...
Dicerna (DRNA) up 78% Today. Being Acquired by Novo Nordisk (NVO) for $38.00.
We shoot and we score. Up 1,133% since adding to Watch List @ $3.00.
Our second...
Avicanna (AVCNF) $0.60 Conference Call.
8:30EST This Morning, Friday 11/12/21
Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call.
TORONTO,...
And We Have Our First MEME Stock! $2.00 to $29.95.
Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)
Guess we were bound to stumble across...
ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites
Gentleman, Start Your Engines?
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Cybin (CYBN) Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using...
October 26, 2021 07:30 AM Eastern Daylight Time
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biotechnology...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
